Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer (vol 8, e54014, 2013)
PLOS ONE(2021)
摘要
[This corrects the article DOI: 10.1371/journal.pone.0054014.].
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要